About the Authors

Hideto Matsui

* ; hide-ped@naramed-u.ac.jp (HM)

Affiliation Department of Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Nara, Japan

Naoko Fujimoto

Affiliations Department of Reprogramming Science, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto, Japan, iCeMS, Kyoto University, Kyoto, Japan

Noriko Sasakawa

Affiliation Department of Reprogramming Science, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto, Japan

Yasuhide Ohinata

Affiliations Life Science Experimental Facility, Department of Biotechnology, Faculty of life and Environmental Sciences, University of Yamanashi, 4-4-37 Takeda, Kofu, Yamanashi, Japan, PRESTO, Japan Science and Technology Agency (JST), Saitama, Japan

Midori Shima

Affiliation Pediatrcs, Nara Medical University, Kashihara, Nara, Japan

Shinya Yamanaka

Affiliations Department of Reprogramming Science, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto, Japan, iCeMS, Kyoto University, Kyoto, Japan, Gladstone Institute of Cardiovascular Disease, San Francisco, California, United States of America

Mitsuhiko Sugimoto

Affiliation Department of Regulatory Medicine for Thrombosis, Nara Medical University, Kashihara, Nara, Japan

Akitsu Hotta

* ; hide-ped@naramed-u.ac.jp (HM)

Affiliations Department of Reprogramming Science, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto, Japan, iCeMS, Kyoto University, Kyoto, Japan, PRESTO, Japan Science and Technology Agency (JST), Saitama, Japan

Competing Interests

M. Shima is a board member of the Feiba and Advate Safety Board in Japan organized by Baxter and a board member of the Benefix Post marketing Surveillance Study Board in Japan organized by Pfizer. M. Shima has received payment for consultancy meetings with Baxter, Pfizer, Biogen Idec, Bayer, CSL Behring, Kaketsuken, Chugai Therapeutic Company and Novo Nordisk, and has received unrestricted grants supporting research from Baxter, Pfizer, Bayer, Kaketsuken, Novo Nordisk, Chugai Pharmaceutical Company and CSL Behring. SY is a member without salary of the scientific advisory boards of iPierian, iPS Academia Japan, Megakaryon Corporation and HEALIOS K. K. Japan. This would not alter our adherence to PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: HM M. Shima M. Sugimoto SY AH. Performed the experiments: HM NF NS AH. Analyzed the data: HM AH. Contributed reagents/materials/analysis tools: YO. Contributed to the writing of the manuscript: HM AH.